SkinBioTherapeutics PLC (SBTX) - Total Liabilities
Based on the latest financial reports, SkinBioTherapeutics PLC (SBTX) has total liabilities worth GBX2.71 Million GBX (≈ $329.31 USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See SkinBioTherapeutics PLC (SBTX) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
SkinBioTherapeutics PLC - Total Liabilities Trend (2016–2025)
This chart illustrates how SkinBioTherapeutics PLC's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see SkinBioTherapeutics PLC (SBTX) total assets.
SkinBioTherapeutics PLC Competitors by Total Liabilities
The table below lists competitors of SkinBioTherapeutics PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Provexis plc
LSE:PXS
|
UK | GBX230.95K |
|
GETT Gold Inc
V:GETT
|
Canada | CA$18.53 Million |
|
Kavango Resources PLC
LSE:KAV
|
UK | GBX937.00K |
|
Checkit PLC
LSE:CKT
|
UK | GBX8.70 Million |
|
International Zeolite Corp
V:IZ
|
Canada | CA$2.88 Million |
|
SysGroup PLC
LSE:SYS
|
UK | GBX14.56 Million |
|
Europa Oil & Gas Holdings
LSE:EOG
|
UK | GBX6.00 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down SkinBioTherapeutics PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See SBTX net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.84 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SkinBioTherapeutics PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SkinBioTherapeutics PLC (2016–2025)
The table below shows the annual total liabilities of SkinBioTherapeutics PLC from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | GBX2.71 Million ≈ $329.31 |
+20.55% |
| 2024-06-30 | GBX2.25 Million ≈ $273.17 |
+274.61% |
| 2023-06-30 | GBX599.34K ≈ $72.92 |
-1.68% |
| 2022-06-30 | GBX609.61K ≈ $74.17 |
+17.31% |
| 2021-06-30 | GBX519.67K ≈ $63.23 |
+70.48% |
| 2020-06-30 | GBX304.83K ≈ $37.09 |
+151.23% |
| 2019-06-30 | GBX121.33K ≈ $14.76 |
-42.03% |
| 2018-06-30 | GBX209.29K ≈ $25.46 |
+76.38% |
| 2017-06-30 | GBX118.66K ≈ $14.44 |
+252.72% |
| 2016-06-30 | GBX33.64K ≈ $4.09 |
-- |
About SkinBioTherapeutics PLC
SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the sympt… Read more